nanoform
small is powerful

Q3

Interim Report

JANUARY–SEPTEMBER 2023

Nanoform's January–September 2023 review:

Project Blockbuster is progressing well. The clinical manufacture of nanoformed material for the project has been done and our partner has successfully made tablets. The clinical trials are expected to start before year end and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial supply agreements is during 2024. Revenues continue to be hampered by low signings in 2H22 and the gross margin by costs related to Project Blockbuster, but the operative free cash flow continues to improve. The balance sheet remains solid with EUR 52m in cash and no debt. In October, Nanoform announced that it had granted AstraZeneca Plc a global online STARMAP® license.

7–9/2023 key financials

- Revenue was impacted by slow signings during 2H22 and decreased to EUR 0.6 million, compared with EUR 0.9 million in 7–9/2022.
- The gross profit decreased to EUR 0.3 million, with a gross margin of 53% (EUR 0.8 million, 96% in 7–9/2022) due to GMP QC costs related to the Blockbuster project.
- Total operating costs* remained unchanged at EUR 5 million (EUR 5 million).
- The number of employees grew to 165 (143) compared with one year ago.
- EBITDA came in at EUR -4.4 million (EUR -4.2 million).
- The operative free cash flow improved to EUR -4.9 million (-6.0 million).
- Basic EPS was EUR -0.05 (EUR -0.07).
- Cash position** was EUR 51.8 million on September 30, 2023 (EUR 76.3 million).

1–9/2023 key financials

- Revenue came in at EUR 2.2 million, stemming from 32 different customer projects (EUR 2.5m, 33 projects in 1–9/2022).
- The gross profit decreased to EUR 1.4 million, with a gross margin of 66% (EUR 2.3 million, 93%) due to GMP QC costs related to the Blockbuster project.
- The number of employees increased to 165 (143).
- Total operating costs* decreased by 2% to EUR 16.4 million (EUR 16.7 million).
- EBITDA came in at EUR -14.2 million (EUR -14.2 million).
- The operating loss was EUR -16.4 million (EUR -16.0 million).
- The operative free cash flow improved to EUR -17.2 million (-21.2 million).
- Basic EPS was EUR -0.20 (EUR -0.22).

(Numbers in brackets refer to the corresponding last year reporting period, unless otherwise mentioned.)

* Defined as materials & services expenses, employee benefit expenses, and other operating expenses
** Including Treasury bills. Part of the cash has been invested in short-term government bond

Significant events during 1–9/2023

- As of January 1, 2023, Antonio da Silva was appointed CBO and a member of the management team.
- Nanoform established a new subsidiary in the UK, Nanoform U.K. Ltd on January 3, 2023.
- On January 10, 2023, the Board of Directors approved share subscriptions based on stock option programs 3/2019, 5/2019 and 1/2020. A total of 29,000 Nanoform Finland Plc new shares were subscribed and the entire subscription price for subscriptions made with the stock options of EUR 34 thousand was entered in the Company's reserve for invested unrestricted equity.
- On February 28, Nanoform announced two new near-term business targets for 2023: "Increased number of non-GMP and GMP projects signed in 2023 vs 2022" and "Improved operating free cash flow in 2023 vs 2022".
- Nanoform's Annual General Meeting (the "AGM") was held on April 12, 2023. The AGM approved the financial statements and discharged the Board of Directors and the CEO of the Company from liability for the financial year 2022. The Meeting decided that no dividend will be paid for the financial year that ended on December 31, 2022. The AGM further resolved the number of members of the Board of Directors to be four and the AGM re-elected Miguel Calado (Chairperson), Mads Laustsen, Albert Hæggström and Jeanne Thoma as ordinary members of the Board of Directors for the next term of office.
- On April 12, 2023, the Board of Directors approved share subscriptions based on stock option programs 2–3/2019 and 1/2020. A total of 37,000 Nanoform Finland Plc new shares were subscribed and the entire subscription price for subscriptions made with the stock options of EUR 41 thousand was entered in the Company's reserve for invested unrestricted equity.
- In April, Nanoform won a new grant from the Bill & Melinda Gates Foundation to work on several of the foundation's drug development projects.
- In May Nanoform's Manufacturer's Authorization and GMP Certificate were updated to include nanoforming of multiple APIs in the GMP facility.
- In June, Nanoform submitted a notification to the Finnish Medicines Agency (Fimea) to update our Manufacturer's Authorization (MIA). The objective of this notification was to include the following in our MIA: Our new production facilities and equipment (GMP2&3), our new Quality Control laboratory (GMP QC) and Nanoforming of APIs to be used in products with a Marketing Authorization. Due to this notification, a GMP inspection is expected to take place during 1Q24.
- Nanoform previously disclosed on November 15, 2021, that it has signed an agreement to manufacture nanoformed GMP

material for a European headquartered international company. Following 12 months of preclinical development work, two privately held European pharmaceutical development and manufacturing organizations decided to join Nanoform and the European headquartered international company in funding the development and commercialization of this more patient centric version of a current blockbuster drug. For this purpose, the parties entered into a collaboration agreement on November 17, 2022. Under the terms of the agreement, Nanoform and the three other parties will fund in equal shares the completion of this development program. In the event that the commercialization is successful, Nanoform expects to retain a 25% share of the net-income received by the parties. In May 2023, after Fimea renewed Nanoform's GMP Certificate, Nanoform commenced the clinical manufacture related to this project.

- In June, Nanoform and Celanese Corporation, a global specialty materials company, provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. The result, presented at the Biotech Outsourcing Strategies Conference in Basel on July 3, 2023, demonstrated significant reduction in the initial burst effect seen commonly in high drug load implants by combining Nanoform's CESS® particles with Celanese's Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants. Notably they also demonstrated that nanoformed particles can enable longer sustained release properties for long-acting drug products and smaller implants. This opens up many possibilities for drug developers.
- The clinical manufacture related to project Blockbuster was successfully completed and the produced nanomaterial was released and shipped for manufacture of the final drug product. Clinical trials are expected to commence in 4Q23 and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial supply agreements is during 2024.
- Quality Director and Accountable Director Johanna Kause became a member of Nanoform's management team as of September 1st, 2023. Johanna Kause, who is responsible for all matters related to quality, has been with the company since January 2021.
- We received notice of allowance from the United States Patent and Trademark Office (USPTO) for our US patent application (US17947490) directed at the process we have developed to nanoform biological molecules. We are encouraged by this positive response that reflects our innovative work also in the field of large molecules. We have filed several patent applications directed at the biologics nanoforming technology in other jurisdictions that are currently pending. Following granted patents in the United States, Japan, and Canada, we also received notification from the European Patent Office (EPO) of their intention to grant our corresponding European patent application (EP15793857.2) directed at the CESS® technology for manufacture of our small molecule nanoparticles.
- We conducted promising initial *in vitro* trials with two major pharma companies looking at monoclonal antibodies (mAb's). These results further strengthen our proposition that nanoparticles are relevant for improved product development and more patient centric commercial products in the field of mAb's and we look forward to advancing these developments with our pharma clients.
- During 1–9/2023 17 new non-GMP projects and one GMP project were signed, both with new and repeat customers, both US and Europe based. We also signed our first major pharma customer from Japan.
- During 1–9/2023 one new non-GMP line was commissioned, taking the total number of lines to 19 non-GMP lines and one GMP line. GMP lines 2&3 will be commissioned after they are inspected and approved by Fimea, with a recently updated new expected timeline of sometime during 1Q 2024.

Significant events after 1–9/2023

- In October, Nanoform announced that its customer TargTex S.A. had been granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas. The orphan drug designation follows the generation of a preclinical rodent data package in which a survival advantage was shown for this nanoform-enabled medicine candidate. The hydrogel nanoformulation developed by Nanoform enabled a 200-fold increase in drug load compared to bulk and a 5-fold increase in drug load compared to nanomilling. Hence Nanoform's proprietary technology and nanoformulation expertise will enable TargTex's drug candidate TTX101 to move towards clinic. TargTex is currently raising funds to take this innovative treatment to clinic and is planning a phase 1/2a clinical trial in recurrent glioblastoma (GBM) patients across the US and EU, in which nanoformed TTX101 is applied as adjunct to surgery after tumour excision.
- In October, Nanoform announced that it had granted AstraZeneca Plc a global online STARMAP® license. STARMAP® is a digital AI version of the CESS® technology that enables *in silico* experiments to determine which molecules should be nanoformed. The license will enable AstraZeneca to screen molecules from drug discovery through to lifecycle management. As part of this licensing agreement, Nanoform will receive access to compound libraries and large data sets to undertake STARMAP® screening and propose innovative product development concepts and strategies in collaboration with AstraZeneca. This comes after several years of early-stage collaboration between Nanoform and AstraZeneca and a successfully completed technology evaluation partnership including STARMAP® which has resulted in clinical candidate feasibility studies. STARMAP® is well aligned with AstraZeneca's ambitious sustainability goals.

STARMAP® Online has been created as a direct request from Nanoform's current and future partners who seek to maintain the level of confidence STARMAP® offers, while integrating it into their own in-house molecule-selection processes. STARMAP® Online creates the opportunity for clients to perform large numbers of *in silico* CESS® experiments from their desktop. This approach further supports Nanoform's green ambition by ensuring that Nanoform progresses the molecules with the greatest probability of success. STARMAP® Online offers:

- Security and safety – the interface has been developed in alignment with ISO27001:2017 standards.
- Client submissions are confidential and seen only by clients (not by Nanoform), allowing molecules to be screened without sharing structures. Outputs are presented directly to the client via the system.
- Scalability and agility: The ability to manage thousands of molecules in a single submission to support the selection of candidates from molecule libraries is possible.
- Novel insights: STARMAP® Online holds a database of some 20,000 pre-analyzed, public-domain disclosed drugs and candidates. Clients can request thematic evaluations and understand the power of CESS® in different therapeutic areas, target classes, and disease areas.

Project Blockbuster and ASDs (amorphous solid dispersions)

During the reporting period we completed the manufacture of nanoformed active pharmaceutical ingredient ("API") for Project Blockbuster, an important milestone in preparation for the clinical trial due to start before year end. This is a great opportunity for us to show that small is a powerful ingredient in formulation.

Due to the inherent poor solubility of the API, the current formulation of this blockbuster medicine has been an amorphous solid dispersion ("ASD"). Amorphous API materials are notoriously unstable, and therefore require high amounts of polymers to stabilize the API - leading to a low drug load in the product and therefore, in the case of oral solid products, often to a high number of large tablets that need to be taken by the patient. This is a known problem, in particular for patient populations with challenges to swallow. The nanocrystalline formulation developed by Nanoform offers an attractive alternative with a substantially higher drug load in the final drug product and consequently a reduced tablet burden for the patient. We are encouraged by the early interest shown in this patient centric reformulation from both the originator as well as value added medicine companies and we look forward to the readout from the study, expected in 1Q 2024.

In addition to the patient benefit, we can with our proprietary technology offer opportunities to extend IP protection for the reformulated and improved product, expecting that in many cases our innovative formulations will be patentable. Importantly, current ASD based medicines are often protected by secondary patents that claim aspects of the ASD formulation. These secondary patents, such as in the case of the product in Project Blockbuster, often extend by several years the expiration of the primary patent claiming the API. In the case of Project Blockbuster, we believe that our nanocrystalline formulation is not in the scope of the patents claimed in the ASD formulation. This would potentially enable entry earlier into the market, in the jurisdictions where the ASD formulation patents remain active, compared to ASD based generic formulations.

ASDs remain a leading formulation strategy for poorly soluble APIs, particularly for oral solid dosage forms. There are currently some 50 marketed medicines that are ASDs and these sell in aggregate for more than USD 15bn in the US annually. We are currently looking at several other marketed ASD opportunities to replicate our early successes with Project Blockbuster in addition to those ASDs still in the global drug development pipeline. According to STARMAP®, almost 80 per cent of the 46 ASDs we so far have starmapped may be well suited to be nanoformed by CESS®.

Nanoform's Q3 2023 Interim Report

Helsinki, Finland – Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, will publish its Q3 2023 interim report on November 22, 2023, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.

The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO Christian Jones. The presentation will be delivered in English.

The presentation will be broadcast live as a webcast available at:
https://ir.financialhearings.com/nanoform-q3-report-2023

Teleconference dial-in numbers:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference.
https://conference.financialhearings.com/teleconference/?id=5005133

CEO's review

We continue our progress on multiple fronts. During Q3 we set a new production record towards kg scale per hour with more than 90% collection efficiency on a R&D line. This achievement is important as we prepare for 2024's major milestone of manufacturing 100kg of nanoformed GMP material for the pivotal EU&US studies and registration batch related to project Blockbuster. This project has progressed well and all involved parties are excited. We also see significant external interest in the project. The nanoformed material for the pilot PK study was shipped during Q3 to our partner, who now successfully has produced tablets. Clinical trials are expected to commence soon and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial supply agreements is during 2024.

We also saw positive momentum in our ongoing GMP project with TargTex, as the Portuguese biotech company was granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas. The orphan drug designation followed the generation of a preclinical rodent data package in which a survival advantage was shown for this nanoform-enabled medicine candidate. The hydrogel nanoformulation developed by Nanoform enabled a 200-fold increase in drug load compared to bulk and a 5-fold increase in drug load compared to nanomilling. Hence Nanoform's proprietary technology and nanoformulation expertise enabled TargTex's drug candidate TTX101 to move towards clinic. TargTex, currently raising funds to take this innovative treatment to a phase 1/2a clinical trial in recurrent glioblastoma patients across the US and EU, recently received positive news that it had been awarded EUR 14m for clinical validation by the EU-EIC accelerator program.

We are also making clear progress with rolling out STARMAP®, our digital AI version of a CESS® line, in the pharma industry. Last month we granted AstraZeneca Plc a global online STARMAP® license that will enable AstraZeneca to screen molecules from drug discovery through to lifecycle management to determine which molecules should be nanoformed. As part of this licensing agreement, Nanoform will receive access to compound libraries and large data sets to undertake STARMAP® screenings and propose innovative product development concepts and strategies in collaboration with AstraZeneca. After the press release we have seen a clear increased interest in the AI tool also from other large pharma organizations.

We have continued to be busy on the regulatory side. As you remember, in May, after an inspection by Fimea, Nanoform's Manufacturer's Authorization and GMP Certificate were updated to include nanoforming of multiple APIs in our GMP facility. In June, we submitted a notification to Fimea to include our new production facilities and equipment (GMP2&3), our new GMP QC laboratory (this will help our gross margin return to the 90+ levels we target) and the nanoforming of APIs to be used in products with a Marketing Authorization. The 'used in products with a Market Authorization' is important from a strategic point of view and is related to our Blockbuster project. As a result of the June filing, a GMP inspection is now expected to take place during 1Q24, slightly later than the November slot we had prepared for, but still it would mean our second inspection within 12 months, which can be considered impressive for a company our size. As we expect several GMP projects to materialize in the coming quarters, keeping planned timelines is key both from a service quality and a cost perspective. Our ambition is clear, we want to get as high customer net promoting scores when executing multiple GMP projects in parallel as we have received when running many non-GMP projects in parallel.

On the BD side we are making solid progress among large pharma, while the biotech sector still is hampered by tough funding conditions. While we only signed one new non-GMP deal during the summer, the ongoing discussions point to a solid interest in our technology and we expect to sign more deals in 2023 and 2H23 compared with the same period last year. We also have clearly more - by number and depth - strategic discussions with large and mid sized pharma compared to a year ago.

Progress has also been made on the operating free cash flow, which continued to see an improvement in 3Q23 without help from the topline yet. We expect the improvement in operating free cash flow to continue, despite the temporary increased costs from project Blockbuster and the fact that we do not yet have our otherwise ready GMP QC laboratory approved by Fimea. This is a clear testimony to the determination and teamwork of the Nanoformers. The swiftness with which we have been able to change focus from investing & building to improving productivity & cash flow while at the same time serving a large number of customers has been impressive.

For Nanoform the previous years were about building a capable organization and making large investments. During 2023 we have focussed on productivity increases and improved operating free cash flow, working towards our 2025 midterm business target of becoming cash flow positive. The way to execute that is nontrivial but clear; to grow the topline and keep the operating costs and capital expenditure under control. We have already made tangible progress on the two latter areas and expect the former to improve as well in the coming quarters and years, as we do an increasing amount of GMP work. Any larger milestone payments would naturally also have a significant impact. We've now reached a critical mass where we can serve dozens of clients in parallel on non-GMP projects, manufacture GMP material for several clinical trials annually, while helping our clients overcome their pharmaceutical development challenges. At the same time, we see significant potential to improve productivity and to increase the output of our quite impressive fleet of nanoforming lines and related capabilities.

I look forward with confidence and excitement to the coming quarters and years. The problem with bioavailability is enormous, our brand recognition and service offering have continued to strengthen, the global pharma industry's response to that has been growing, and our strong balance sheet is a positive aspect when partners evaluate us. We'll continue to work relentlessly towards our 2025 mid-term business targets, while executing as fast as possible on our near-term targets. None of this can be done without our amazing employees and great partners. My sincere THANK YOU to you all for your continued dedication to Nanoform and for the inspiring and innovative work for which we're known.

Best Regards,

Prof. Edward Hæggström, CEO Nanoform

Nanoform Group's key figures

Financial KPI's

EUR thousand	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022	1–12/2021	1–12/2020
Revenue	641	851	2,166	2,501	3,487	1,955	687
Revenue growth %	-25%	79%	-13%	92%	78%	185%	n.m.
Gross profit	340	816	1,422	2,334	3,147	1,792	497
Gross margin	53%	96%	66%	93%	90%	92%	72%
EBITDA	-4,380	-4,186	-14,245	-14,243	-19,027	-17,745	-18,196
Operating loss	-5,102	-4,796	-16,354	-15,979	-21,409	-19,705	-19,423
Loss for the period	-4,122	-5,155	-15,417	-16,506	-22,075	-19,690	-19,441
Basic EPS (EUR)	-0.05	-0.07	-0.20	-0.22	-0.29	-0.29	-0.35
Net debt	-45,486	-69,220	-45,486	-69,220	-61,807	-68,070	-54,156
Net debt excluding lease liabilities	-51,818	-76,329	-51,818	-76,329	-68,740	-75,733	-59,977
Investments in property, plant, and equipment	-503	-1,857	-2,931	-6,920	-8,965	-7,737	-2,336
Operative free cash flow	-4,883	-6,044	-17,176	-21,164	-27,992	-25,482	-20,532
Cash and cash equivalents excluding short-term government bonds (end of period)	18,432	76,329	18,432	76,329	68,740	75,733	61,025
Cash and cash equivalents including short-term government bonds (end of period)	51,818	76,329	51,818	76,329	68,740	75,733	61,025

Operational KPI's

	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022	1–12/2021	1–12/2020
Number of new customer projects signed during the period							
Non-GMP	1	2	17	15	17	16	10
GMP			1		1	2	
Total number of new customer projects	**1**	**2**	**18**	**15**	**18**	**18**	**10**
Number of lines (end of the period)							
Non-GMP	19	16	19	16	18	14	8
GMP	1	1	1	1	1	1	1
Total number of lines (end of period)	**20**	**17**	**20**	**17**	**19**	**15**	**9**
Personnel at the end of reporting period	165	143	165	143	150	125	74

Company near-term business targets for 2023 (reiterated)

- Increased number of non-GMP and GMP projects signed in 2023 vs 2022
- Improved operating free cash flow in 2023 vs 2022

Company mid-term business targets 2025 (reiterated)

- To nanoform at least 70 new Active Pharmaceutical Ingredients (API) annually
- To have in place 35 operating production lines of which 7 to 14 are expected to be GMP production lines
- Over 90 percent gross margin
- To have 200–250 employees
- To be cash flow positive

Smaller particle size can improve a drug's bioavailability



The surface area increases 30 fold from a 10 micron[1] sized particle once the particle size is reduced to 100nm

Reduction of particle size down to 50nm increases the surface area by 1,000 fold

Small is powerful – Nanoform in brief

Nanoform Finland Plc is a public company offering expert services in nanotechnology and drug particle engineering for the global pharma industry. The company works with its partners to overcome drug development and delivery challenges through its game-changing technologies and novel formulation and GMP manufacturing capabilities.

Nanoform's services span the full range from small- to large-molecule drugs, and the company has a growing pipeline of customers that represent global large, mid-sized and specialty pharmaceutical as well as biotechnology companies.

Nanoform's mission is to enable a significant increase in the number of drugs that progress to clinical trials and reach the market. The company targets the pharmaceutical developers and manufacturers of drugs for which safety and efficacy could be improved by increased bioavailability or novel drug delivery routes. Nanoform's size reduction technologies, including its patented and scalable CESS® technology and its biologics platform, vastly increase the surface area of drug particles to enhance bioavailability or open up more patient-centric, local drug delivery routes.

Nanoform has not outsourced or out-licensed its patent protected technologies, to keep control of its technology, service offering and know-how.

Our technologies – Controlled Expansion of Supercritical Solutions (CESS®)

Nanoform's patented CESS® technology has demonstrated its ability to produce crystalline or stable amorphous nanoparticles below 200 nm, and at times as small as 10 nm, from solution without the use of solvents, excipients, or complex production processes. The application of the CESS® technology platform provides an opportunity for Nanoform's customers to improve and tune the particle properties of their small-molecule APIs – for example, size, shape, and polymorphic structure, thus improving API solubility and bioavailability.

The CESS® technology may reduce the failure of drugs during clinical trials by enhancing the performance and safety of APIs. It can also allow drugs that previously failed in clinical trials to be revisited and potentially achieve success. In addition, it may improve the pharmacokinetic properties of drugs (both in the pharmaceutical pipeline and those already on the market), and provide new commercial opportunities for drugs. Ultimately, the benefits unlocked by CESS® will be felt by patients as the technology enables more and enhanced new drugs to reach the market.

STARMAP®– The digital twin of CESS®

STARMAP® Online is a predictive sparse-data AI-based platform that can be applied to pick the winners among candidate molecules. It augments historical experimental results with detailed expert knowledge to determine which APIs are most likely to achieve success through the CESS® nanoparticle engineering process.

STARMAP® presents an opportunity for the rational design of patient-centric drug development, and can be applied to novel APIs, as well as existing brands, to ensure that the projects with the highest chances of success are targeted, avoiding wasted resources and improving efficiency. STARMAP® is currently available as a subscription to Nanoform's customers, which can be accessed online.

1. Supercritical CO_2 is guided into a pressure vessel loaded with API
2. Increasing the pressure and temperature in the vessel dissolves the API in supercritical CO_2
3. The CO_2 and the API are released from the pressure vessel and the flow, pressure and temperature profiles are accuartely controlled
4. The pressure and temperature is controlled to achieve a stable nucleation phase and formation of nanoparticles
5. In a collection vessel the CO_2 is sublimated resulting in final nanoparticles ready for collection and formulation



Biologics

Nanoform's biologics technology is a gentle bottom-up process that nanoforms large-molecule therapeutics, reducing their particle size to as small as 50 nm while retaining their biological activity.

As the technology does not necessitate harsh conditions such as high temperatures, it has wide applicability even for temperature-sensitive therapeutic biomolecules, such as enzymes, and can be applied to large molecules up to 150 kDa. By reducing particle size, the technology opens up new drug delivery opportunities, and may facilitate enhanced drug loading and tailored release profiles.

Most traditional biologics are administered intravenously, however by utilizing Nanoform's technology, it may be possible to formulate for alternative, more patient-centric administration routes, such as intranasal, pulmonary, or oral delivery.

1. API containing feed solution is pumped into the nebulizer
2. Feed solution is nebulized into a carrier gas
3. Mist is transported into the drying chamber via a connection pipe
4. Mist is dried using low-temperature drying gas
5. Dried particles are charged by the ionizer and collected using electrostatic precipitation



Small is an ingredient in formulation

Formulating nanoformed particles the right way

Our pharmaceutical development team leverages their deep understanding of nanomaterials science and nanoformation expertise to unlock the full potential of nanoformed APIs and deliver formulations that meet customer requirements. Nanoform supports all dosage form development, with specific expertise in oral, inhaled, injectable, and ophthalmic formulations.

The team follows a well-designed formulation development and selection process, with the goal of rapidly progressing drug candidates and optimizing the formulation for the development phase, from preclinical through to clinic and lifecycle.

The benefits of partnering with Nanoform for nanoparticle-optimized formulations can include enhanced bioavailability and the opportunity to reduce dose, simpler formulations, and increased dosage form flexibility. Additional advantages can include reduced side effects, optimized exposure in toxicology studies, and reduced variability in pharmacokinetic parameters.

Nanoform's analytical services ensure consistency

Analytical chemistry plays a crucial role in characterizing and understanding materials made from nanoforming and formulation processes. We use a variety of techniques to analyze our nanoparticles and formulations and ensure that they meet strict quality and safety standards. Our analytical team utilizes state-of-the-art equipment and software to accurately measure the properties of our nanoparticles, including purity, size, shape, and crystallinity. This information is essential for understanding how to develop our formulations and predict how our drugs will interact *in vivo* so as to optimize their efficacy.

Highly-potent APIs can be safely formulated in Nanoform's GMP facilities

Nanoform's globally unique GMP facilities utilize CESS® to manufacture API nanoparticles to GMP standards. The facilities can handle highly-potent APIs (HPAPIs) with occupational exposure limits (OELs) of 30 ng/m^3. Recipe control via automation as well as Wash-in-Place and Clean-in-Place capabilities enable faster and more efficient cleaning between campaigns, reducing the overall downtime of GMP manufacturing, and increasing productivity.

Market outlook

Nanoform operates in one of the world's largest markets, the global pharmaceutical market, whose turnover exceeds USD 1,000 billion and where the annual R&D budget exceeds USD 200 billion. Despite the enormous investments in R&D, less than 50 new drugs have been approved by the FDA annually on average during the last ten years. One of the key reasons why so few medicines are approved each year is low bioavailability of the API. With 70 to 90 percent of new drugs being poorly soluble we expect that the challenges with bioavailability will only increase going forward. Hence, we have seen significant interest in our potentially ground-breaking technology platform from the global pharma market. This broad interest comes from global large, mid-sized, specialty pharmaceutical as well as from biotechnology companies. We expect the high customer interest in our technology offering to continue.

The drug development industry is highly regulated and characterized by a step-by-step development process, from discovery and clinical trials to commercialization. It is considered a defensive industry where the underlying demand is non-cyclical and steadily increasing as the global population grows wealthier and older and as chronic diseases become more prevalent.

The high attrition rate in the global drug development pipeline – with one of the key reasons being low bioavailability – limits the number of new drugs that reach the market. This increases the maturity of pharmaceutical companies' commercial product portfolios, with the average share of revenue stemming from drugs that have been on the market for more than ten years amounting to more than half of their revenue for many of the world's largest pharma companies. With an old product portfolio, the vulnerability to upcoming patent expirations increases as does the importance of lifecycle management of existing drugs. As Nanoform's technology platform provides an opportunity to help not only lower the attrition of new drugs in development but also with lifecycle management of existing drugs on the market, we foresee continued interest in the technology. By providing opportunities for pharma companies to seek to extend patent protection by allowing for patents for, among others, new indications, dosage forms, and delivery mechanisms our technology may create significant value to our customers. Many jurisdictions allow for alternative simplified regulatory pathways, such as section 505(b)(2) of the Federal Food, Drug and Cosmetic Act in the U.S., for already commercialized drugs for which clinical safety or efficacy data is already available.

Nanoform's commercial operations are at an early stage and during the period its business operations have included R&D activities, non-GMP projects, tech transfer to GMP, and manufacture of GMP material. Our existing customers include global large, mid-sized, and specialty pharmaceutical as well as biotech companies. Major pharma companies are in general entities integrated across the entire pharmaceutical value chain and therefore often do the marketing and sales of the drugs they have developed. The price of a drug, set by a pharmaceutical company, is often a function of several factors, e.g., the potential competitive landscape it faces, the need for financing future R&D of novel drug candidates, and the benefit or value the drug is deemed to add for its target group. However, actual pricing mechanisms, including, e.g., potential reimbursement and regulatory restrictions on pricing of drugs, vary between different jurisdictions. Contract development and manufacturing organizations (CDMOs) focus specifically on drug development and manufacturing. Pricing of the services of these companies differs from pricing by pharma companies since CDMOs in general do not, by themselves, commercialize the drugs they develop or manufacture. Instead, the compensation for their services is often based on a combination of compensation for supply of material, milestone payments, royalties, and license payments. While price is an important factor in client negotiations, the most important and decisive factor is how much value the technology and service offer. We believe our proprietary technology offers significant value and hence will be priced with a material premium to traditional technologies.

Financial review for January 1–September 30, 2023

Revenue

Nanoform Group's revenue in January–September decreased by -13% to EUR 2,166 (2,501) thousand.

The revenue in 1–9/23 stemmed from 32 (33) different customer projects. Revenues are recognized over the lifetime of the projects, based on percentage of completion method, where working hours make up a clear majority of the expenses booked for the projects.

Results

Nanoform Group's gross profit decreased to EUR 1,422 (2,334) thousand and the gross margin was 66% (93)% in January–September 2023.

The gross margin was negatively impacted by the increased amount of external GMP QC services related to the GMP manufacture of project Blockbuster. Excluding the cost of the external GMP QC services, our underlying gross margin was above 90% thanks to our new 40m³ CO_2 bulk tank system that was taken into usage in 4Q22 and where the unit cost is a fraction compared with using multiple gas cylinders in the production process. In June Nanoform submitted a notification to Fimea to update our Manufacturer's Authorization. The notification included our new GMP QC laboratory and an inspection is expected to take place during 1Q24. This will help our gross margin return to the 90+ levels we target.

Financial position and cash flows

The loss before tax was EUR -15,402 (-16,486) thousand. Earnings per share was EUR -0.20 (-0.22).

Nanoform Group's total assets at the end of the review period were EUR 82,890 (105,658) thousand, of which equity accounted for EUR 72,019 (92,719) thousand. Cash and cash equivalents were EUR 18,432 (76,329) thousand excluding T-bills. T-bills amounted to EUR 33,385 thousand in the reporting period (balance sheet value). Net debt amounted to EUR –45,486 (-69,220) thousand including T-bills.

Nanoform Group's net cash flow from operating activities in January–September was EUR -13,464 (-15,093) thousand. The change in the working capital was EUR -469 (-1,469) thousand. The Group investments have slowed down significantly as the major part of investments for expanding the manufacturing capacity have been made in previous years (several GMP lines with separate cleanrooms, the 40m³ CO_2 bulk tank system, a new ERP system and a Biologics pilot line for GMP in addition to additional non-GMP production lines). The total cash-based investments amounted to EUR -2,931 (-6,920) thousand. The net cash flow from investing activities was EUR -35,651 (-7,553) thousand including short-term investments to T-bills. Cash flow from financing activities was EUR -870 (23,047) thousand. In the comparable period cash flow was positively affected by a directed share issue in March 2022 increasing the equity by EUR 23,668 thousand net of transaction costs.

Investments, research and development

The Group's investments in property, plant, and equipment in January–September 2023 amounted to EUR 2,931 (6,920) thousand, consisting mainly of investments in additional GMP and non-GMP production lines at the current manufacturing site. Additions to GMP and non-GMP facilities are classified as construction in progress until a GMP Certificate is obtained for the new GMP lines and until they are commissioned for customer projects for new non-GMP production lines.

The Group R&D expenditure recognized as expenses, including internal AI expenses, amounted to EUR 2,396 (3,553) thousand. R&D expenses consist of salaries as well as external R&D services. R&D expenditures are recognized as employee benefit expenses and other operating expenses in the consolidated statement of comprehensive income.

Personnel and the Board of Directors

During the last twelve months the number of employees has grown by 15 per cent and at the end of the review period, the Group had 165 (143) employees representing 35 nationalities. Within Nanoform's international team of highly skilled professionals there are 39 PhD's from different fields including e.g. physics, chemistry, pharma, and biology. Nanoform Group has been able to attract talent with diverse skills. At the end of the review period 23 employees worked in GMP Manufacturing, 47 in R&D (including non-GMP customer projects), and 7 in Customer Project Management. Quality Control had 25 and Quality Assurance 9 professionals. The Commercial team consisted of 9 professionals. The Engineering & Maintenance teams employed 12 employees and Industrialization and Technical Development teams 6 employees. Nanoform has also been able to attract talent in Legal 3 and IT 6 and in corporate functions 18 (e.g., Business Operations, Finance, Procurement, IR, HR).

The company's Annual General Meeting convened on April 12, 2023, re-elected Miguel Calado (Chairperson), Mads Laustsen, Albert Hæggström and Jeanne Thoma as ordinary members to the company's Board of Directors for the next term of office. The CEO was Edward Hæggström.

Shares and shareholders

Nanoform's share is listed on the Premier segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS).

Nanoform's registered share capital amounted to EUR 80,000 (80,000). At the end of the review period, the company had 78,429,964 (78,363,964) shares after share subscriptions by stock options in January and March 2023. The share's volume weighted average price during the review period was EUR 2.04 (4.27) and SEK 23.51 (44.01). The highest price paid during the January–September review period was EUR 3.30 (6.96) and SEK 38.95 (71.10) and the lowest price paid EUR 1.47 (2.93) and SEK 17.15 (32.30). The closing price of the share at the end of review period was EUR 1.78 (3.15) and SEK 21.70 (36.00). The market value of the share capital on September 30, 2023, was EUR 139.6 (246.5) million. Nanoform had more than 9,700 shareholders at the end of the period - some 1,200 more than a year ago - with somewhat more than 70 percent

of them holding EUR nominated shares and somewhat less than 30 percent of them holding SEK nominated shares. The 25 largest shareholders held some 71 percent of all Nanoform's shares and votes at the end of the review period. The ownership structure can be found on Nanoform's internet pages Ownership structure – Nanoform small is powerful. (Source: Monitor by Modular Finance AB. Compiled and processed data from various sources, including Euroclear Sweden, Euroclear Finland and Morningstar)

Share-based incentive plans

During the review period Nanoform had 17 active share-based incentive plans for the members of the Board of Directors, key persons, and employees of the Group: option programs 1–5/2019, 1–5/2020, 1–5/2021, 1/2022 and 1/2023. Based on all the option programs, with strike prices ranging from EUR 1.10 to EUR 9.00 a total maximum number of 4,640,510 shares could potentially be subscribed (For more info see Note 7).

Near-term risks and uncertainties

Nanoform operates in a strictly regulated industry, the pharmaceutical industry. The Group's business is based on new technology that has not yet been widely applied in humans. As Nanoform is still a young company, the viability of its business model has not yet been proven and the Group has been operating at a loss, with no proof so far of being able to sustainably cover its costs with revenues without additional external funding. The most important business-related risks are associated with the Group's growth targets and their achievement with the company's chosen strategy. Industry-related risks are mainly associated with a target market that is both highly regulated and conservative and where adaptation of new technologies can take longer than expected.

Risks associated with the Group's financial position mainly consist of currency-, credit- and counterparty risks as well as the stock market risk from share investment. Foreign exchange fluctuations arise from SEK, GBP, USD, NOK, and JPY currency exposure. The Company's counterparty risks consist mainly of contracts between external customers, suppliers and partners in co-operation and financial institutions. Direct stock market risk stems from the changes in the market value of the owned Herantis Pharma Plc shares. Investments into short-term government bonds (Treasury Bills, duration less than one year) are considered risk free investments from a counterparty (credit risk) point of view but may include currency risk. Nanoform does not hedge its currency or stock market risk. Risks related to legislation, rules and regulatory compliance are associated with the group's sector of industry. For further risk analysis see Nanoform's annual report: Investors – Nanoform small is powerful.

Decisions by the Annual General Meeting and the Constitutive Meeting of the Board of Directors

Nanoform held its Annual General Meeting (the "AGM") for 2023 on April 12, 2023.

The AGM approved the financial statements and discharged the Board of Directors and the CEO of the Company from liability for the financial year 2022. The AGM decided that no dividend will be paid for the financial year that ended on December 31, 2022.

The number of members of the Board of Directors was confirmed to be four and the AGM re-elected Miguel Calado as Chairperson, Mads Laustsen, Albert Hæggström, and Jeanne Thoma as ordinary members of the Board of Directors for the next term of office.

The AGM confirmed a monthly compensation of EUR 8,000 for the Chairman and EUR 5,000 for the Board Members, EUR 2,500 for the Chairman of the Audit and Compensation Committee and EUR 1,500 for the Members of the Audit and Compensation Committee.

The AGM resolved further that the remuneration will be paid in four (4) installments during the term, each installment after the publication of the respective interim report for the periods 1 January 2023 – 31 March 2023, 1 April 2023 – 30 June 2023, 1 July 2023 – 30 September 2023, 1 October 2023 – 31 December 2023. Each board member has undertaken to use approximately 50% of the aforementioned remuneration to purchase shares in the company within two weeks from the publication of the aforementioned interim reports, or as soon as possible in accordance with applicable legislation. The Annual General Meeting also resolved that the travel expenses of the members of the Board of Directors are compensated in accordance with the Company's travel rules.

The AGM resolved that PricewaterhouseCoopers Oy with Tomi Moisio as the auditor in charge were re-elected as the Group's auditor. The Auditor's fee will be paid in accordance with a reasonable invoice approved by the Company.

The AGM authorized the Board of Directors to repurchase Nanoform's own shares. Altogether no more than 7,700,000 shares may be repurchased. The authorization will be valid until the beginning of the next Annual General Meeting.

On April 12, 2023, at the constitutive meeting following the annual general meeting, the Board of Directors resolved to elect as members of the Audit and Compensation Committee (AC): Miguel Calado (Chairperson), Jeanne Thoma (Ordinary member), and Mads Laustsen (Ordinary member). The Audit and Compensation Committee is a permanent committee of the Board of Directors and acts in accordance with its charter as adopted by the Board of Directors.

Condensed financial information January–September 2023

Consolidated statement of comprehensive income

EUR thousand	Note	7-9/2023	7-9/2022	1-9/2023	1-9/2022	1-12/2022
Revenue	4	641	851	2,166	2,501	3,487
Other operating income						
Materials and services		-301	-36	-744	-167	-340
Employee benefits	7	-3,434	-3,029	-10,723	-10,665	-14,010
Depreciation, amortization, and impairment losses	6	-722	-610	-2,109	-1,736	-2,382
Other operating expenses	5	-1,287	-1,973	-4,944	-5,912	-8,164
Total expenses		**-5,744**	**-5,647**	**-18,519**	**-18,481**	**-24,896**
Operating loss		**-5,102**	**-4,796**	**-16,354**	**-15,979**	**-21,409**
Finance income		1,388	106	4,518	601	957
Finance expenses		-401	-461	-3,567	-1,108	-1,604
Total finance income and expenses		**986**	**-355**	**952**	**-507**	**-647**
Loss before tax		**-4,116**	**-5,151**	**-15,402**	**-16,486**	**-22,056**
Income tax		-6	-4	-15	-20	-19
Loss for the period		**-4,122**	**-5,155**	**-15,417**	**-16,506**	**-22,075**
Loss for the period attributable to the equity holders of the parent company		**-4,122**	**-5,155**	**-15,417**	**-16,506**	**-22,075**
Other comprehensive income						
Items that may be reclassified to loss in subsequent periods						
Translation differences		3	6	1	12	4
Other comprehensive income, net of tax		**3**	**6**	**1**	**12**	**4**
Total comprehensive income total		**-4,119**	**-5,149**	**-15,416**	**-16,495**	**-22,071**
Total comprehensive income for the period attributable to the equity holders of the parent company		**-4,119**	**-5,149**	**-15,416**	**-16,495**	**-22,071**
Basic earnings per share, EUR		-0.05	-0.07	-0.20	-0.22	-0.29
Diluted earnings per share, EUR		-0.05	-0.07	-0.20	-0.22	-0.29

The company's potential dilutive instruments consist of stock options. As the company's business has been unprofitable, stock options would have an anti-dilutive effect and therefore they are not taken into account in measuring the dilutive loss per share.

Consolidated statement of financial position

EUR thousand	Note	Sep 30, 2023	Sep 30, 2022	Dec 31, 2022
ASSETS				
Non-current assets				
Intangible assets		505	374	383
Property, plant, and equipment	6	26,819	24,539	27,127
Investments in shares		1,701	2,074	1,923
Other receivables		292	288	288
Total non-current receivables		**29,316**	**27,275**	**29,721**
Current assets				
Inventories		143		6
Trade receivables		396	514	829
Other receivables		139	226	274
Investments in short-term government bonds	9	33,385		
Prepaid expenses and accrued income		1,077	1,314	1,071
Cash and cash equivalents	8	18,432	76,329	68,740
Total current assets		**53,573**	**78,382**	**70,920**
Total assets		**82,890**	**105,658**	**100,641**
EQUITY AND LIABILITIES				
Equity				
Share capital		80	80	80
Reserve for invested unrestricted equity		152,644	152,569	152,569
Accumulated deficit		-65,289	-43,423	-43,362
Loss for the period		-15,417	-16,506	-22,075
Total equity		**72,019**	**92,719**	**87,212**
Non-current liabilities				
Lease liabilities	8	5,262	6,092	5,896
Advances received				
Trade payables				
Total non-current liabilities		**5,262**	**6,092**	**5,896**
Current liabilities				
Provisions		51	0	
Lease liabilities	8	1,070	1,018	1,037
Advances received		374	872	447
Trade payables		1,098	2,042	1,192
Other liabilities		293	202	233
Accrued expenses	10	2,722	2,713	4,624
Total current liabilities		**5,609**	**6,847**	**7,533**
Total liabilities		**10,871**	**12,939**	**13,429**
Total equity and liabilities		**82,890**	**105,658**	**100,641**

Consolidated statement of changes in equity

EUR thousand	Share capital	Reserve for invested unrestricted equity	Translation differences	Accumulated deficit	Total equity
At January 1, 2023	**80**	**152,569**	**6**	**-65,443**	**87,212**
Loss for the period				-15,417	-15,417
Other comprehensive income					
Translation differences			1		1
Transactions with equity holders of the Company					
Increase of the share capital					
Share subscription with stock options		75			75
Share issue*					
Share-based payments				147	147
At September 30, 2023	**80**	**152,644**	**7**	**-80,713**	**72,019**

* Netted transaction costs EUR 0 thousand

EUR thousand	Share capital	Reserve for invested unrestricted equity	Translation differences	Accumulated deficit	Total equity
At January 1, 2022	**80**	**128,599**	**2**	**-44,187**	**84,494**
Loss for the period				-16,506	-16,506
Other comprehensive income					
Translation differences			12		12
Transactions with equity holders of the Company					
Increase of the share capital					
Share subscription with stock options		303			303
Share issue*		23,668			23,668
Share-based payments				750	750
At September 30, 2022	**80**	**152,569**	**14**	**-59,944**	**92,719**

* Netted transaction costs EUR 892 thousand

EUR thousand	Share capital	Reserve for invested unrestricted equity	Translation differences	Accumulated deficit	Total equity
At January 1, 2022	**80**	**128,599**	**2**	**-44,187**	**84,494**
Loss for the period				-22,075	-22,075
Other comprehensive income					
Translation differences			4		4
Transactions with equity holders of the Company					
Increase of the share capital					
Share subscription with stock options		303			303
Share issue*		23,668			23,668
Share-based payments				819	819
At December 31, 2022	**80**	**152,569**	**6**	**-65,443**	**87,212**

* Netted transaction costs EUR 892 thousand

Consolidated statement of cash flow

EUR thousand	Note	1–9/2023	1–9/2022	1–12/2022
Cash flow from operating activities				
Loss before tax		-15,402	-16,486	-22,056
Adjustment for:				
Depreciation, amortization, and impairment losses	6	2,109	1,736	2,382
Finance income and expenses		-918	507	647
Share-based payments	7	147	750	785
Other adjustments*		132	9	37
Change in net working capital:				
Trade and other receivables		281	-724	-1,408
Trade payables and other liabilities		-613	-745	-607
Change in other receivables (non-current)		-4	-2	-2
Change in inventory		-137		-6
Interest paid			-202	-204
Interest received		955	85	373
Paid tax		-15	-20	-19
Net cash used in operating activities		**-13,464**	**-15,093**	**-20,080**
Cash flow from investing activities				
Payments for intangible assets		-193	-133	-160
Payments for property, plant, and equipment	6	-2,931	-6,920	-8,965
Investments in short-term government bonds		-32,884		
Payments for investments		357	-499	-499
Net cash used in investing activities		**-35,651**	**-7,553**	**-9,625**
Cash flow from financing activities				
Proceeds from share issues			24,560	24,560
Transaction costs from the share issues			-892	-892
Acquisitions of treasury shares				
Share subscription with stock options		75	303	303
Repayment of R&D loans				
Repayment of lease liabilities	8	-946	-924	-1,233
Net cash from financing activities		**-870**	**23,047**	**22,737**
Net increase (+) decrease (-) in cash and cash equivalents		**-49,986**	**401**	**-6,968**
Cash and cash equivalents at the beginning of period		68,740	75,733	75,733
Effects of exchange rate changes on cash and cash equivalents		-321	196	-25
Cash and cash equivalents at the end of the period		**18,432**	**76,329**	**68,740**
Cash and cash equivalents and short-term government bonds at the end of period		51,316	76,329	68,740

* Other adjustments

EUR thousand	1–9/2023	1–9/2022	1–12/2022
Lease adjustments		7	12
Other operating expenses - provision for onerous contract	51		-1
Other adjustments -provision for credit loss	81	2	26
Total	**132**	**9**	**37**

Selected notes

1. Company information

Nanoform ("Nanoform", "Group") is an international group offering nanoforming, formulation and analytical services for the global pharma and biotech industry. The parent company, Nanoform Finland Plc (formerly Nanoform Finland Ltd, the "Company") is a company organized under the laws of Finland and its business ID is 2730572-8. The registered address of the head office is Viikinkaari 4, 00790 Helsinki, Finland.

2. Accounting policies

This financial information for the January–September 2023 periods has been prepared in accordance with IAS 34 Interim Financial Reporting. In preparation of this report, Nanoform has applied the same accounting policies, methods of computation and presentation as in the financial statements for the year ended December 31, 2022.

Nanoform Group was formed in 2020 after Nanoform USA Inc. was established in the USA. In 2023, another subsidiary was established in the UK (Nanoform U.K. Ltd). The consolidated financial statements include the parent company, Nanoform Finland Plc, and the subsidiaries in the USA and in the UK. The parent company holds 100% ownership of its subsidiaries. The subsidiaries are consolidated using the acquisition method. All intragroup transactions, receivables, liabilities, and unrealized gains are eliminated in the consolidated financial statements.

The consolidated financial statements are presented in euros, which is the functional currency of the parent company. The statements of comprehensive income and the statements of cash flows of foreign subsidiaries, whose functional currency is not euro, are translated into euro at the average exchange rates for the reporting period. The statements of financial position of such subsidiaries are translated at the exchange rate prevailing at the reporting date. Translation differences resulting from the translation of profit for the period and other items of comprehensive income in the statement of comprehensive income and statement of financial position are recognized as a separate component of equity and in other comprehensive income. Also, the translation differences arising from the application of the acquisition method and from the translation of equity items cumulated subsequent to acquisition are recognized in other comprehensive income. The figures in this report have been rounded and consequently the sum of individual figures may deviate from the presented sum figure.

The preparation of interim and annual reports requires management to make decisions, estimates and assumptions that affect the application of accounting policies and the recognized amounts of assets, liabilities, revenue, and expenses. Estimates and judgements are reviewed regularly. The Group's management has used judgment to review, analyze and evaluate revenue recognition for non-GMP and GMP projects. Nanoform recognizes revenue over time as the project performance does not create an asset with an alternative use to the Nanoform Group and the Nanoform Group has an enforceable right to payment for performance to date. The Group's management has used judgment when evaluating the leasing agreements e.g., the options to renew and terminate the leasing agreements at specific dates, the probability of Nanoform using these options and by determining the appropriate discount rate for the leasing agreements. The management has also used judgment to evaluate the economic lifetime of property, plant, and equipment. Management will review technological development regularly in the future to ensure that property, plant, and equipment are carried at no more than at their recoverable amount.

Nanoform's Board of Directors has approved this report in its meeting on November 21, 2023. This report is not audited or reviewed by the auditors of the Group.

3. Significant changes during the reporting period

The Group's results of operations have fluctuated significantly from period to period in the past and are likely to do so in the future. The financial position and performance of the Group was particularly affected by the following events and transactions during the reporting period:

- Revenue decreased slightly due to the lower order intake in 2H/2022. Revenue consists of multiple projects in which the Group has offered nanoforming, formulation and analytical services for the global pharma and biotech industry. (See note 4 Segment information and revenue).
- Employee benefit expenses continued to represent the majority of the Group's total operating expenses during the review period. Employee benefit expenses consisted of short-term employee benefit expenses (mainly salaries), post-employment benefit expenses (defined contribution pension plans) and share-based payments (stock options). The employee headcount increased by 15% to 165 (143), while the total employee benefit expenses increased by 0.5% to EUR 10,723 (10,665) thousand in the review period.
- Other operating expenses included premises expenses, IT expenses, marketing and communication expenses, external consultant and professional fees, travel expenses, voluntary personnel related expenses, external R&D expenses, and other expenses. The main reason for the decrease in the other operating expenses compared with the same period last year

is the decrease in the IT expenses, SAP S4/HANA was implemented in January 2023 (see note 5 Other operating expenses).

- Finance income and expenses stemmed from changes in foreign exchange rates in SEK, GBP, USD, NOK and JPY currencies and fair market value changes in the owned Herantis Pharma shares as well as interest income and expenses.
- Nanoform has invested part of its cash into short-term government bonds issued by Nordic (Finland, Sweden, Norway) and European (Germany, France) governments in order to diversify and decrease bank risk. The short-term government bonds are planned to be held until maturity and measured at amortized cost applying the interest rate method. In the future Nanoform may include UK and US T-bills as part of cash management.
- Share subscriptions based on stock option programs approved by the Board of Directors on January 10, 2023 and on April 12, 2023. The total subscription price for subscriptions made with stock options of EUR 75 thousand was booked in the reserve for invested unrestricted equity.
- The change in property, plant, and equipment book value is mainly related to completed constructions in non-GMP lines and quality control equipment. GMP 2&3 construction are classified in progress until new GMP certificates are obtained. Additions to non-GMP facilities are classified as construction in progress until non-GMP production lines are commissioned (see note 6 Property, plant, and equipment).

4. Segment information and revenue

Nanoform offers nanoforming, formulation, and analytical services for the global pharma and biotech industry. Nanoform's chief operating decision maker is the Chief Executive Officer (CEO). The CEO manages the Group as one integrated business and hence, the Group has one operating and reportable segment.

Nanoform's revenue during the reported period is recognized from customer contracts in Europe and the United States (defined by the domicile of customer). The Group's strategy is to offer expert services widely in order to minimize dependence from a single customer or project. Nanoform's revenue consists of non-GMP and GMP projects related to nanoforming, formulation and analytical services provided to customers globally. Nanoform's customer contracts include one or multiple performance obligations. In the customer contracts, every separate nanoformed API is considered as a separate performance obligation, as the customer can receive benefit from every single separately nanoformed API. Nanoform recognizes revenue over time as the project performance does not create an asset with an alternative use to the Nanoform Group and the Nanoform Group has an enforceable right to payment for performance to date. During the reporting period revenue from two separate customer projects is over 10% of the total cumulative revenue. The following table summarizes the revenue breakdown:

EUR thousand	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022
Europe	334	478	1,199	1,393	1,961
United States	307	373	966	1,108	1,526
Total	**641**	**851**	**2,166**	**2,501**	**3,487**

EUR thousand	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022
Services transferred over time	641	851	2,166	2,501	3,487
Total	**641**	**851**	**2,166**	**2,501**	**3,487**

5. Other operating expenses

The decrease in other operating expenses stems mainly from the decrease in IT expenses (SAP S4/ HANA was implemented in early January 2023).

EUR thousand	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022
Premises expenses	53	38	176	101	159
IT expenses	178	536	803	1,725	2,064
Marketing and communication expenses	158	206	423	548	825
Consultant and professional fees	301	288	958	927	1,355
Travel expenses	63	83	276	250	353
Voluntary personnel related expenses	113	167	466	580	781
R&D expenses - external	204	251	748	616	1,008
Other expenses	217	405	1,093	1,164	1,620
Total	**1,287**	**1,973**	**4,944**	**5,912**	**8,164**

6. Property, plant, and equipment

Nanoform's property, plant, and equipment consists of leased premises and apartments (right-of-use assets), improvements to leased premises, machinery and equipment and construction in progress.

The right-of-use assets consist of Nanoform's leased premises. Construction in progress consists of expenses related to new GMP lines, and non-GMP lines as well as the new equipment related to quality control which do not yet fulfill the activation criteria. Minor part of the PPE construction in progress has been reclassified to computer software during 2Q2023.

EUR thousand	Machinery and equipment	Right-of-use assets	Improvements to leasehold premises	Construction in progress	Total
Net book value at January 1, 2023	5,295	6,437	1,125	14,271	27,128
Additions	183	193	8	1,659	2,043
Disposals*	-165				-165
Reclassification	1,885		424	-2,458	-149
Depreciations	-1,110	-795	-133		-2,038
Net book value at September 30, 2023	**6,088**	**5,835**	**1,424**	**13,472**	**26,819**
Net book value at January 1, 2022	3,465	7,213	1,233	7,807	19,718
Additions	288	237	36	6,141	6,701
Disposals*		-37		-153	-190
Reclassification	2,048		6	-2,054	
Depreciations	-793	-789	-109		-1,690
Net book value at September 30, 2022	**5,008**	**6,624**	**1,167**	**11,740**	**24,539**
Net book value at January 1, 2022	3,465	7,213	1,233	7,807	19,718
Additions	384	332	31	9,277	10,024
Disposals*		-56		-241	-297
Reclassification	2,565		6	-2,571	
Depreciations and impairments**	-1,120	-1,053	-145		-2,317
Net book value at December 31, 2022	**5,295**	**6,437**	**1,124**	**14,272**	**27,127**

* Disposals consist of the changes in right-of-use assets due to shortening of leasing period. Disposals in machinery and equipment and construction in progress are mainly due to changes in materiality considerations.
** Impairments consist of changes in machinery and equipment carrying amount due to fast technological development.

7. Share-based payments

Nanoform has 17 share-based incentive plans: Option programs 1–5/2019, 1–5/2020, 1–5/2021, 1/2022 and 1/2023. The option programs are targeted to members of the Board of Directors, key persons, and employees of the Group. Many of the employees are included in the share-based incentive plans. The 1–5/2019 share-based incentive plans are valid until further notice. The 1–5/2020, 1–5/2021, 1/2022 and 1/2023 share-based incentive plans have vesting periods from 6 to 12 months from the grant date. The effect of all stock options booked to the earnings of the review period was EUR 147 (750) thousand.

The factors used to determine the fair value and the end of the subscription periods of the 2019, 2020, 2021, 2022 and 2023 stock option programs are presented in the following table.

Option program	Fair value of the Company share at grant date, EUR	Subscription price of the Company share with options, EUR	Volatility, %	Risk free interest rate, %	Fair value of the option, EUR	End of the share subscription period
01–05/2019	1.30–1.62	1.10	64.85	0.01	0.74–1.00	Until further notice
01–05/2020	1.77–4.30	1.65–5.00	43.25–64.85	-0.55–0.01	0.97–2.11	Mar 10, 2025–Oct 23, 2025
01–05/2021	5.97–7.50	9.00	44.97–47.62	0.01	1.72–2.49	Apr 6, 2026–Aug 27, 2026
01/2022	3.52	9.00	42.5	1.33	0.65	June 6, 2027
01/2023	2.02	2.5	48.25	3.01	0.79	Sept 11, 2028

8. Net debt

The book value of Nanoform's net debt is summarized in the table below:

EUR thousand	Sep 30, 2023	Sep 30, 2022	Dec 31, 2022
Cash and cash equivalents	-18,432	-76,329	-68,740
Short-term government bonds	-33,385		
Net debt excluding lease liabilities	**-51,818**	**-76,329**	**-68,740**
Current lease liabilities	1,070	1,018	1,037
Non-current lease liabilities	5,262	6,092	5,896
Net debt	**-45,486**	**-69,220**	**-61,807**

9. Financial assets and liabilities

Sep 30, 2023 EUR thousand	Fair Value Hierarchy	Financial assets at fair value	Financial assets at amortized cost	Carrying amount	Fair value
Quoted shares	1	1,701		1,701	1,701
Short-term government bonds	2		33,385	33,385	
Trade receivables	2		396	396	396
Other receivables	2		139	139	139
Cash and cash equivalents	2		18,432	18,432	18,432
Total		**1,701**	**52,353**	**54,054**	**20,668**

Sep 30, 2023 EUR thousand	Fair Value Hierarchy	Financial liabilities at fair value	Financial liabilities at amortized cost	Carrying amount	Fair value
Trade payables	2		1,098	1,098	1,098
Lease liabilities	2		6,332	6,332	6,332
Total			**7,430**	**7,430**	**7,430**

There has not been any transfers between fair value levels during the year 2022–2023.

Sep 30, 2022 EUR thousand	Fair Value Hierarchy	Financial assets at fair value	Financial assets at amortized cost	Carrying amount	Fair value
Quoted shares	1	2,074		2,074	2,074
Short-term government bonds	2				
Trade receivables	2		514	514	514
Other receivables	2		226	226	226
Cash and cash equivalents	2		76,329	76,329	76,329
Total		**2,074**	**77,069**	**79,143**	**79,143**

Sep 30, 2022 EUR thousand	Fair Value Hierarchy	Financial liabilities at fair value	Financial liabilities at amortized cost	Carrying amount	Fair value
Trade payables	2		2,042	2,042	2,042
Lease liabilities	2		7,109	7,109	7,109
Total			**9,151**	**9,151**	**9,151**

Dec 31, 2022 EUR thousand	Fair Value Hierarchy	Financial assets at fair value	Financial assets at amortized cost	Carrying amount	Fair value
Quoted shares	1	1,923		1,923	1,923
Short-term government bonds	2				
Trade receivables	2		829	829	829
Other receivables	2		274	274	274
Cash and cash equivalents	2		68,740	68,740	68,740
Total		**1,923**	**69,843**	**71,766**	**71,766**

Dec 31, 2022 EUR thousand	Fair Value Hierarchy	Financial liabilities at fair value	Financial liabilities at amortized cost	Carrying amount	Fair value
Trade payables	2		1,192	1,192	1,192
Lease liabilities	2		6,933	6,933	6,933
Total			**8,124**	**8,124**	**8,124**

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the group is the current bid price.

Level 2: Financial instruments that are not traded in an active market are valued using valuation procedures that minimize the reliance on entity-specific estimations and maximize the use of observable market data to calculate their fair value. An instrument is included in level 2 if all relevant inputs needed to determine its fair value are observable.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

10. Related party transactions

Related parties are the persons or entities related to any of the companies belonging to the Nanoform Group. The definition of related parties of the Group is based on the definitions included in the international IAS 24 standards.

Compensation recognized as an expense for the members of the Board of Directors:

	1–9/2023		
EUR thousand	Fees	Fees settled in shares	Share-based payments
Miguel Maria Calado	32	32	
Albert Hæggström, CFO	15	15	17
Mads Laustsen	20	20	
Jeanne Thoma	20	20	
Total	**87**	**87**	**17**

	1–9/2022		
EUR thousand	Fees settled in cash	Fees settled in shares*	Share-based payments
Miguel Maria Calado	91	79	19
Albert Hæggström, CFO	43	36	68
Mads Laustsen	55	49	12
Jeanne Thoma	55	49	37
Total	**244**	**213**	**136**

	1–12/2022		
EUR thousand	Fees settled in cash	Fees settled in shares*	Share-based payments
Miguel Maria Calado	91	79	19
Albert Hæggström, CFO	43	37	83
Mads Laustsen	55	49	12
Jeanne Thoma	55	49	37
Total	**244**	**214**	**151**

* Fees settled in shares include transfer tax.

Compensation for CEO and Management team:

	1–9/2023		
EUR thousand	Salaries and other short-term employee benefits	Post-employment benefits	Share-based compensation
CEO	229	41	
Management team*	868	151	43
Total	**1,097**	**192**	**43**

	1–9/2022		
EUR thousand	Salaries and other short-term employee benefits	Post-employment benefits	Share-based compensation
CEO	228	43	
Management team*	1,070	122	127
Total	**1,298**	**165**	**127**

	1–12/2022		
EUR thousand	Salaries and other short-term employee benefits	Post-employment benefits	Share-based compensation
CEO	295	40	
Management team*	1,354	229	224
Total	**1,649**	**269**	**224**

* The management team without CEO, whose employee benefit expenses are presented separately.

Liabilities to key management

The following related party balance is included in the consolidated statement of financial position:

EUR thousand	Sep 30, 2023	Sep 30, 2022	Dec 31, 2022
Liabilities to key management	32	131	156
Total	**32**	**131**	**156**

11. Commitments and contingencies

The Group commitments to purchase of services and property, plant, and equipment (mainly related to new GMP and non-GMP lines) amounted to EUR 2,471 (4,382) thousand at the end of the review period.

The Group's management is not aware of any open disputes or litigations, which could have a significant impact on the Group's financial position. At the reporting date the Group doesn't have any contingent liabilities.

12. Events after the review period

- In October, Nanoform announced that its customer TargTex S.A. had been granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas. The orphan drug designation follows the generation of a preclinical rodent data package in which a survival advantage was shown for this nanoform-enabled medicine candidate. The hydrogel nanoformulation developed by Nanoform enabled a 200-fold increase in drug load compared to bulk and a 5-fold increase in drug load compared to nanomilling, which did not achieve the results needed. Hence Nanoform's proprietary technology and nanoformulation expertise will enable TargTex's drug candidate TTX101 to move towards clinic. TargTex is currently raising funds to take this innovative treatment to clinic and is planning a phase 1/2a clinical trial in recurrent glioblastoma (GBM) patients across the US and EU, in which nanoformed TTX101 is applied as adjunct to surgery after tumour excision.
- In October, Nanoform announced that it had granted AstraZeneca Plc a global online STARMAP® license. STARMAP® is a digital AI version of the CESS® technology that enables *in silico* experiments to determine which molecules should be nanoformed. The license will enable AstraZeneca to screen molecules from drug discovery through to lifecycle management. As part of this licensing agreement, Nanoform will receive access to compound libraries and large data sets to undertake STARMAP® screening and propose innovative product development concepts and strategies in collaboration with AstraZeneca. This comes after several years of early-stage collaboration between Nanoform and AstraZeneca and a successfully completed technology evaluation partnership including STARMAP® which has resulted in clinical candidate feasibility studies. STARMAP® is well aligned with AstraZeneca's ambitious sustainability goals.

STARMAP® Online has been created as a direct request from Nanoform's current and future partners who seek to maintain the level of confidence STARMAP® offers, while integrating it into their own in-house molecule-selection processes. STARMAP® Online creates the opportunity for clients to perform large numbers of *in silico* CESS® experiments from their desktop. This approach further supports Nanoform's green ambition by ensuring that Nanoform progresses the molecules with the greatest probability of success.

Appendix 1

Key figures

EUR thousand	7–9/2023	7–9/2022	1–9/2023	1–9/2022	1–12/2022	1–12/2021	1–12/2020
Revenue	641	851	2,166	2,501	3,487	1,955	687
Revenue growth %	-25%	79%	-13%	92%	78%	185%	n.m.
Gross profit	340	816	1,422	2,334	3,147	1,792	497
Gross margin	53%	96%	66%	93%	90%	92%	72%
EBITDA	-4,380	-4,186	-14,245	-14,243	-19,027	-17,745	-18,196
Operating loss	-5,102	-4,796	-16,354	-15,979	-21,409	-19,705	-19,423
Loss for the period	-4,122	-5,155	-15,417	-16,506	-22,075	-19,690	-19,441
Basic EPS (EUR)	-0.05	-0.07	-0.20	-0.22	-0.29	-0.29	-0.35
Net debt	-45,486	-69,220	-45,486	-69,220	-61,807	-68,070	-54,156
Net debt excluding lease liabilities	-51,818	-76,329	-51,818	-76,329	-68,740	-75,733	-59,977
Investments in property, plant, and equipment	-503	-1,857	-2,931	-6,920	-8,965	-7,737	-2,336
Operative free cash flow	-4,883	-6,044	-17,176	-21,164	-27,992	-25,482	-20,532
Cash and cash equivalents excluding short-term government bonds (end of period)	18,432	76,329	18,432	76,329	68,740	75,733	61,025
Cash and cash equivalents including short-term government bonds (end of period)	51,818	76,329	51,818	76,329	68,740	75,733	61,025
Personnel at the end of reporting period	165	143	165	143	150	125	74

Calculation of key figures

Key figure	Definition	Reason to the use
Revenue growth %	Percentage increase in revenue between two periods of time	Revenue growth indicates the success of the Nanoform business in its growth trajectory
Gross profit	Revenue + Other operating income - Materials and services	Gross profit is the margin, which the Group generates, when its service production related expenses has been decreased
Gross margin	Gross profit/revenue	A complement to the absolute gross profit, showing the proportion of income that is left after direct material costs and external services have been subtracted from the revenues
EBITDA	Operating loss before depreciation, amortization, and impairments	EBITDA is an indicator of the operating result before investments, i.e. a proxy for cash flow generated by operations, if investments roughly equals depreciations
Loss for the period	Loss for the period as presented in the comprehensive income statement	Loss for the period shows the net profit for the Group's owners
Basic EPS	The loss for the period/the weighted average number of ordinary shares during the year	Measure describes the division of profit to each share
Net debt	Short-term loans + Long-term loans + Short-term lease liabilities + Long-term lease liabilities - Cash and cash equivalents	Net debt is an indicator to measure the total external debt financing of Nanoform
Net debt excluding lease liabilities	Short-term loans + Long-term loans - Cash and cash equivalents	Net debt excluding lease liabilities is an indicator to measure the total external debt financing of Nanoform without lease liabilities
Investments in property, plant, and equipment	Investments in property, plant, and equipment as presented in cash flow statement	Measure generates further information for the cash flow needs of investments
Operative free cash flow	EBITDA - growth capex	Free cash flow indicates the cash flow that is largely available for e.g. paying dividends

Further enquiries:

Albert Hæggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150

Henri von Haartman,
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11

Financial calendar

February 29, 2024, Annual Review 2023,
Financial Statements Review 2023

nanoform
small is powerful